1. Home
  2. TRIN vs EOLS Comparison

TRIN vs EOLS Comparison

Compare TRIN & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TRIN
  • EOLS
  • Stock Information
  • Founded
  • TRIN 2007
  • EOLS 2012
  • Country
  • TRIN United States
  • EOLS United States
  • Employees
  • TRIN N/A
  • EOLS N/A
  • Industry
  • TRIN Finance/Investors Services
  • EOLS Biotechnology: Pharmaceutical Preparations
  • Sector
  • TRIN Finance
  • EOLS Health Care
  • Exchange
  • TRIN Nasdaq
  • EOLS Nasdaq
  • Market Cap
  • TRIN 786.4M
  • EOLS 787.7M
  • IPO Year
  • TRIN 2021
  • EOLS 2018
  • Fundamental
  • Price
  • TRIN $14.26
  • EOLS $13.04
  • Analyst Decision
  • TRIN Strong Buy
  • EOLS Strong Buy
  • Analyst Count
  • TRIN 3
  • EOLS 6
  • Target Price
  • TRIN $15.17
  • EOLS $22.60
  • AVG Volume (30 Days)
  • TRIN 508.5K
  • EOLS 676.4K
  • Earning Date
  • TRIN 10-30-2024
  • EOLS 11-06-2024
  • Dividend Yield
  • TRIN 14.28%
  • EOLS N/A
  • EPS Growth
  • TRIN 12.74
  • EOLS N/A
  • EPS
  • TRIN 1.72
  • EOLS N/A
  • Revenue
  • TRIN $205,164,000.00
  • EOLS $248,326,000.00
  • Revenue This Year
  • TRIN $35.34
  • EOLS $33.57
  • Revenue Next Year
  • TRIN $17.55
  • EOLS $32.91
  • P/E Ratio
  • TRIN $8.28
  • EOLS N/A
  • Revenue Growth
  • TRIN 20.08
  • EOLS 34.42
  • 52 Week Low
  • TRIN $13.05
  • EOLS $9.29
  • 52 Week High
  • TRIN $15.44
  • EOLS $17.82
  • Technical
  • Relative Strength Index (RSI)
  • TRIN 58.75
  • EOLS 38.46
  • Support Level
  • TRIN $14.04
  • EOLS $11.88
  • Resistance Level
  • TRIN $14.37
  • EOLS $12.67
  • Average True Range (ATR)
  • TRIN 0.21
  • EOLS 0.74
  • MACD
  • TRIN 0.06
  • EOLS -0.16
  • Stochastic Oscillator
  • TRIN 92.05
  • EOLS 27.51

About TRIN Trinity Capital Inc.

Trinity Capital Inc is a closed-end, non-diversified management investment company. The company is engaged in providing debt, including loans and equipment financings, to growth-stage companies, including venture-backed companies and companies with institutional equity investors. Its equipment financings involve loans for general or specific use, including acquiring equipment, secured by the equipment or other assets of the portfolio company.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Share on Social Networks: